Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-1459
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JNJ-1459 is an oral small-molecule interleukin-17 (IL-17) inhibitor developed by Johnson & Johnson/Janssen as a targeted therapy for moderate to severe plaque psoriasis. It is designed to inhibit IL-17A binding to its receptor, thereby blocking downstream pro‑inflammatory signaling pathways that drive keratinocyte activation and psoriatic plaque formation.[1][3][5][10] As an antipsoriatic agent and new molecular entity, JNJ-1459 advanced to phase 2 clinical development in plaque psoriasis before Johnson & Johnson discontinued the program as part of broader portfolio reprioritization.[1][5][6][11]
02
Targets
IL-17A (Interleukin-17A)
Beyond the preview
Go deeper on JNJ-1459.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-1459.